| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Vaxcyte, Inc. (PCVX) has 6 insiders with recent SEC Form 4 filings, including 0 buys and 25 sells. PCVX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 496.9K | $25.65M | - | |
| COO | 160.7K | $8.30M | - | |
| CFO | 104.4K | $5.39M | - | |
| Other | 76.0K | $3.92M | - | |
| VP | 29.0K | $1.50M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2024 | Pickering Grant50 | Chief Executive Officer | Sale+OE | 15,000 | $61.92 | $928,845.00 | -3.0% | +38.1% | -45.5% | |
| Apr 18, 2024 | Guggenhime Andrew46 | President And CFO | Sale+OE | 8,000 | $61.27 | $490,199.41 | -4.0% | +34.2% | -49.4% | |
| Apr 1, 2024 | Eydelman Mikhail67 | SVP, Gen Counsel &Corp Sec | Sale+OE | 1,667 | $66.73 | $111,234.14 | -2.6% | +15.3% | -51.7% | |
| Apr 1, 2024 | Wassil Jim53 | Chief Operating Officer | Sell | 3,000 | $66.69 | $200,065.55 | -0.7% | +15.3% | -51.7% | |
| Apr 1, 2024 | Pickering Grant50 | Chief Executive Officer | Sell | 2,616 | $66.71 | $174,501.51 | -0.4% | +15.3% | -51.7% | |
| Mar 25, 2024 | Pickering Grant50 | Chief Executive Officer | Sale+OE | 15,000 | $66.93 | $1,003,978.40 | -1.5% | +14.2% | +8.3% | |
| Mar 18, 2024 | Guggenhime Andrew46 | President And CFO | Sale+OE | 8,000 | $69.02 | $552,143.75 | -4.0% | +5.6% | +9.8% | |
| Mar 1, 2024 | Wassil Jim53 | Chief Operating Officer | Sell | 3,000 | $73.71 | $221,133.89 | -0.4% | -2.1% | +1.8% | |
| Mar 1, 2024 | Cowan Elvia68 | SVP, Finance | Sale+OE | 11,678 | $74.08 | $865,070.44 | -18.4% | -2.1% | +1.8% | |
| Mar 1, 2024 | Eydelman Mikhail67 | SVP, Gen Counsel &Corp Sec | Sale+OE | 1,667 | $73.73 | $122,906.84 | -1.7% | -2.1% | +1.8% |